Wird geladen...
Current Status: Site-Specific Antibody Drug Conjugates
Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as div...
Gespeichert in:
| Veröffentlicht in: | J Clin Immunol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer US
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891387/ https://ncbi.nlm.nih.gov/pubmed/27003914 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-016-0265-6 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|